Sex-Disaggregated Trials Are a Commercial Move.
Not a compliance cost. Blended efficacy compresses the value story of drugs that work better in women. Sex-stratified endpoints unlock label precision, HTA pricing power, and a population that is reliably adherent.
The compression problem, by example
Imagine a phase-three trial of a novel anti-inflammatory for a chronic cardiovascular indication. The trial enrolls 1,000 patients in a 55:45 male:female ratio, a fair approximation of current pivotal trial enrollment patterns for cardiovascular indications. The drug reduces hospitalisation by 10 percent in the male cohort and 33 percent in the female cohort. The pre-specified primary endpoint is the blended cohort effect. The published number is 21 percent. An HTA body looks at 21 percent and produces a price that reflects 21 percent.
The commercial team now has a single number to sell into a system that produces heterogeneous outcomes it is not allowed to name. The stronger female-cohort result, the 33 percent reduction, is legible only inside the supplementary tables. It does not appear in the label. It does not anchor payer negotiation. It does not differentiate against a competitor whose own trial produced 22 percent aggregate. The value that exists is obscured by the way the trial was specified.
Why the commercial consequence is not a rounding error
The HTA bodies that matter, NICE in the UK, IQWiG in Germany, HAS in France, CADTH in Canada, PBAC in Australia, operate on incremental-cost-effectiveness thresholds. A 33 percent reduction in a specified population crosses cost-effectiveness thresholds that a 21 percent reduction in an unspecified population does not. The difference between the two numbers is not statistical. It is the difference between a reimbursed product at a strong price and a delisted or heavily discounted product.
In addition, female-skewed populations across multiple therapeutic areas (autoimmune, rheumatology, endocrinology, migraine, mental health) exhibit higher long-term adherence and lower drop-off than male-skewed populations. The commercial LTV of the female segment, once captured, is structurally higher. The incentive alignment is already there; the trial design has to be willing to see it.
Illustrative numbers. Magnitudes will vary by indication, geography, and competitive set. The directional asymmetry (stratified-design commercial value materially exceeds blended-design commercial value when a true sex differential exists) is consistent across indications where the differential has been retrospectively analysed.
The trial-design moves that capture the value
Four operational changes close the gap. None of them is methodologically difficult.
- Pre-specify sex as a stratification factor at randomisation. This is table-stakes and most competent biostatistics groups already do it. What is missing is the pre-specification that the sex-stratified analysis will be a labelled key-secondary endpoint, not a subgroup-analysis footnote.
- Power the trial for the sex-stratified effect. If the investigators plausibly expect a 33 percent female effect and a 10 percent male effect, the trial should be powered to detect both separately at the label-meaningful threshold. This costs an incremental enrolment fraction, not a doubling.
- Seek a sex-labelled indication path with regulators at end-of-Phase-2. The FDA, EMA, and PMDA will all entertain sex-specific indication language when pre-discussed. The obstacle is historically commercial-team reluctance to look "gender-specific" in a marketing context. That reluctance is a legacy of a pre-Biosimilar era; modern specialty-market segmentation already operates at finer granularity than sex.
- Build the HTA dossier with the sex-stratified cost-effectiveness model as the primary submission. This is the step where the pricing power materialises. HTA bodies will accept sex-stratified cost-effectiveness when it is offered. They will not request it spontaneously.
The evidence is not hypothetical
Sex-differential drug response is documented across widely prescribed classes. The chart below shows the direction and approximate magnitude of the documented effect, with each row sourced to a peer-reviewed or regulatory reference. The point is not that every drug needs a sex-specific label; it is that the differentials are large enough that pricing and positioning decisions made without them are, on the current evidence, leaving value unlocked.
Bar direction encodes which sex is favoured by the documented effect; bar length encodes approximate magnitude. Some effects (aspirin stroke prevention, anti-CGRP response) favour the female cohort; others (first-MI prevention, checkpoint-inhibitor OS) favour the male cohort. The commercial implication is agnostic to direction: pricing power comes from labelling the cohort where the drug performs, not from wishing the average were higher.
Where the argument is already working
In HRT, migraine preventatives (anti-CGRP monoclonals such as erenumab, fremanezumab, galcanezumab), and endometriosis disease-modifiers (GnRH antagonists such as elagolix and relugolix), sponsors have moved to explicit female-specific labels and captured the commercial consequence. Pricing and uptake in each of those categories has exceeded the counterfactual where the same drug was launched with a blended label. The categories where the argument is not yet working are the ones where the drug is perceived as "general" (cardiovascular, anti-inflammatory, metabolic) and the female differential, while measurable, has been left in the supplementary tables.
The commercial ask
Pharma sponsor commercial teams should commission, for every Phase 2b or Phase 3 asset in a therapeutic area with a plausible sex differential, a one-page retrospective on historical trial data: was the sex differential present? How large? Would the HTA arithmetic have moved at a different pricing anchor? The output of that exercise informs whether to pre-specify sex stratification in the upcoming pivotal. The cost of the exercise is trivial. The pricing consequence, per the illustrative waterfall above, is not.
The reframe this essay argues for is narrow. It does not ask pharma to be generous. It asks pharma to notice where its current trial architecture is leaving pricing power on the table.
Related reading: A Structural Consolidation of Female Biology for the underlying pharmacokinetic and immunological drivers; Inflammation Is the Unifying Frame for cross-indication commercial opportunity; Pricing the Pathway for the insurance-side alignment.